Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | PHASE1 | RECRUITING | 100 | — | — | Jun 30, 2023 | Oct 30, 2027 | May 5, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (Biopsy) | EXPERIMENTAL | Participants within 2 weeks of starting the first dose of 177Lu-girentuximab |
| Cohort 2 (Biopsy) | EXPERIMENTAL | Participants within 2 weeks of Cycle 4 |
| Cohort 3 (Biopsy) | EXPERIMENTAL | Participants at the time of progression or at 20 months post treatment |
| Name | Type | Description |
|---|---|---|
| 177Lu girentuximab | DRUG | Given by IV (vein) |
| Nivolumab | DRUG | Given by IV (vein) |
| Cabozantinib | DRUG | Given by PO |
| ArabinoFuranosylGuanine [18F]F-AraG | DRUG | Given by IV (vein) |
Inclusion Criteria: 1. Has the ability to understand and willingness to sign a written ICF before the performance of any study-specific procedures on this protocol and 2022-0515 2. Age ≥ 18 years 3. Has locally advanced or metastatic RCC with predominantly clear cell subtype 4. Has at least one mea...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |